1
Home
Companies

Beyond Air

#10190

Rank

$15.13M

Marketcap

US United States

Country

Beyond Air
Leadership team

Mr. Steven Adam Lisi (CEO & Chairman)

Mr. Amir Avniel (Co-Founder, Chief Bus. Officer & Director)

Mr. Douglas Quinton Larson (CFO, Principal Financial Officer & Principal Accounting Officer)

Products/ Services
Biopharma, Biotechnology, Developer Platform, Medical Device, Therapeutics
Number of Employees
50 - 100
Headquarters
Garden City, New York, United States
Established
2011
Company Registration
SEC CIK number: 0001641631
Traded as
XAIR
Social Media
URL
https://www.beyondair.net
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
History

Beyond Air was founded in 2015 and launched an initial public offering in October 2018. It is headquartered in Los Angeles, California and has operations in both the U.S. and Europe.

Mission
Our mission is to utilize our technology to improve the lives of people living with respiratory and other diseases while continuing to develop our medical technology platform to enable precision in minimally invasive treatments.
Vision
Our vision is to be a global leader in precision medicine, providing physicians and patients with the ability to access innovative treatments and treatments that are tailored to their needs.
Key Team

Mr. Michael A. Gaul (Chief Operating Officer)

Edward Barger (Head of Investor Relations)

Mr. Adam Newman (Chief Legal Officer & Gen. Counsel)

Ms. Rebecca Van Doren (Head of Sales)

Ms. Kori-Ann Taylor (Head of Marketing)

Prof. Andrew R. Colin M.D. (Chief Medical Officer & Member of Scientific Advisory Board)

Dr. Giora Davidai M.D. (Chief Medical Officer)

Recognition and Awards
Beyond Air has won several awards for innovation, including Fast Company's 2020 Innovation by Design award and the North American Commercial Innovation in Healthcare award, as well as the Wall Street Journal's 2020 Healthcare Technology & Innovation Award.
References

https://in.investing.com/equities/ait-therapeutics

https://finance.yahoo.com/quote/XAIR/profile?p=XAIR

https://www.crunchbase.com/organization/ait

https://companiesmarketcap.com/

https://www.beyondair.net

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Beyond Air
Leadership team

Mr. Steven Adam Lisi (CEO & Chairman)

Mr. Amir Avniel (Co-Founder, Chief Bus. Officer & Director)

Mr. Douglas Quinton Larson (CFO, Principal Financial Officer & Principal Accounting Officer)

Products/ Services
Biopharma, Biotechnology, Developer Platform, Medical Device, Therapeutics
Number of Employees
50 - 100
Headquarters
Garden City, New York, United States
Established
2011
Company Registration
SEC CIK number: 0001641631
Traded as
XAIR
Social Media
URL
https://www.beyondair.net